Scholarlink

<p>While cancer has traditionally been considered a genetic disease, mounting evidence indicates an important role for non-genetic (epigenetic) mechanisms. Common anti-cancer drugs have recently been observed to induce the adoption of non-genetic drug-tolerant cell states, thereby accelerating the evolution of drug resistance. This confounds conventional high-dose treatment strategies aimed at maximal tumor reduction, since high doses can simultaneously promote non-genetic resistance. In this work, we study optimal dosing of anti-cancer treatment under drug-induced cell plasticity. We show that the optimal dosing strategy steers the tumor to a fixed equilibrium composition between sensitive and tolerant cells, while precisely balancing the trade-off between cell kill and tolerance induction. The optimal equilibrium strategy ranges from applying a low dose continuously to applying the maximum dose intermittently, depending on the dynamics of tolerance induction. We finally discuss how our approach can be integrated with in vitro data to derive patient-specific treatment insights.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal dosing of anti-cancer treatment under drug-induced plasticity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Einar Bjarki Gunnarsson,
  • Benedikt Vilji Magnússon,
  • Jasmine Foo

摘要

While cancer has traditionally been considered a genetic disease, mounting evidence indicates an important role for non-genetic (epigenetic) mechanisms. Common anti-cancer drugs have recently been observed to induce the adoption of non-genetic drug-tolerant cell states, thereby accelerating the evolution of drug resistance. This confounds conventional high-dose treatment strategies aimed at maximal tumor reduction, since high doses can simultaneously promote non-genetic resistance. In this work, we study optimal dosing of anti-cancer treatment under drug-induced cell plasticity. We show that the optimal dosing strategy steers the tumor to a fixed equilibrium composition between sensitive and tolerant cells, while precisely balancing the trade-off between cell kill and tolerance induction. The optimal equilibrium strategy ranges from applying a low dose continuously to applying the maximum dose intermittently, depending on the dynamics of tolerance induction. We finally discuss how our approach can be integrated with in vitro data to derive patient-specific treatment insights.